Issues for consideration at the WHO Executive Board

Distinguished members of the Executive Board of WHO,

On behalf of the People’s Health Movement and a number of affiliated networks I submit the comments and suggestions included below regarding some of the items appearing on the agenda of the WHO Executive Board. We hope that you may find time to read and consider these comments before the relevant discussions at the EB. We hope that you find them useful.

PHM is a global network of organizations working locally, nationally and globally for ‘health for all’. Our basic platform is articulated in the People’s Charter for Health which was adopted at the first People’s Health Assembly in December 2000. More information about PHM can be found at www.phmovement.org.

PHM is committed to a stronger WHO, adequately funded, with appropriate powers and playing the leading role in global health governance. PHM follows closely the work of WHO, through the governing bodies and the secretariat. Across our networks we have technical experts and grass roots organizations with close interests in many of the issues coming before you over the next week. However, WHO does not make it easy for civil society NGOs to contribute to its consideration of the issues coming before it. It limits the number of organizations which have a formal relationship with WHO and has recently restricted access to spaces in the Palais de Nations during the WHA. It seems that WHO is more welcoming of private sector organizations than people’s organizations. A different model of consultation was evident during the work of the Commission on Social Determinants and Health.

Over the last week members of the PHM WHO liaison group have been working through the EB Agenda with the assistance of high level experts from a number of collaborating networks and NGOs. This workshop was part of our Global Health Governance Initiative which involves both watching and advocacy. In the course of these discussions we have prepared the following comments on some of the key issues coming before you.

Members of the PHM WHO liaison group will be following the discussion at the EB over the next week and would be keen to discuss these comments with you during this week.
4.1 Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits

Secretariat note
The Open-Ended Working Group of Member States on Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines and other benefits will meet in December 2010. A report on this meeting and other technical consultations undertaken to support the Group’s work will be made to the Sixty-fourth World Health Assembly, through the Executive Board, as decided in resolution WHA63.1.

PHM Comment
The provisions of the Convention on Biological Diversity provide for benefit sharing where biological samples such as viral material are transferred internationally. Resolution WHA60/28 provides a clear direction for managing this issue.

The H5N1 and H1N1 crises have shown the need for an equitable and transparent mechanism for pandemic preparedness that puts public health as a top priority over industry’s profits.

A viable and sustainable system for pandemic preparedness must include sustainable forms of benefit sharing; ad hoc donations are unreliable solutions. This means that recipients of influenza biological materials must commit to benefit sharing on a mandatory basis. This is important to achieve public health objectives as well as to ensure compliance with international obligations under the Convention of Biological Diversity (CBD) to which almost all WHO member states (except for the US) are a party to. The CBD requires that those that receive and use genetic resources must share benefit arising from the use of those resources.

A Standard Material Transfer Agreement (SMTA), constructed as a formal contractual agreement between the provider of biological resource and the recipient of such resource, is a practical way of achieving concrete benefit sharing. MTAs have been used in the sharing of influenza biological material previously and there are no reasons why standardised MTAs should not now be mandated for use in the transfer of influenza biological materials. SMTA must have a contractual binding effect, and contain terms and conditions on the use of influenza biological material as well as benefit sharing to be an effective solution.

Claims of private intellectual property rights over the influenza biological resources or over the products/processes developed using such material should not be allowed by WHO linked centres or by third parties. If third parties are allowed to claim IPRs over the products/processes developed using such material then royalty free licenses must be made available to developing countries.

The definition of PIP biological material in the Framework must include parts of the biological material in particular their genetic and other components and parts thereof, including genes (RNA and DNA), genes sequences and polynucleotides as well as the polypeptides they encode. It further includes sequence data.

The co-chairs of the OEWG should invite civil society organizations to make written submissions as many such organization may be unable to participate the inter-sessional consultations in person due to funding constraints.
4.3 Public health, innovation and intellectual property

Secretariat note: The Consultative Expert Working Group on Research and Development: Financing and Coordination

The Director-General will propose a composition of the Consultative Expert Working Group to the Board for approval, drawing on the roster of experts whose details, following consultation with Regional Committees, have been submitted to the Director-General through the respective Regional Directors, and taking into account regional representation according to the composition of the Executive Board, gender balance and diversity of expertise, and the Regional Committees’ recommendations.

PHM Comment

The Director-General proposes to recommend the composition of the Consultative Expert Working Group on Research and Development: Financing and Coordination to the Board for approval.

The issues on which the CEWG will provide advice are of critical importance in terms of finding workable mechanisms for mobilizing funds for research and development in relation to pharmaceuticals and other medical products. The use of the patent system to raise (some of the) money for research and development has failed the tests of access and equity and appears to be failing with respect to innovation also. However, large pharmaceutical corporations are reluctant to consider such a significant change in their way of doing business and have opposed moving away from this model.

The credibility of WHO will not be enhanced if non-transparent mechanisms for assembling the CEWG leave scope for concluding that conflict of interest conventions were not followed in evaluating the options before this group. In particular we are concerned to note that an employee of a large pharmaceutical corporation is recommended. It was our understanding that WHO’s conflict of interest policy would preclude such involvement in a norm setting forum, which clearly this is. We recommend that the appointment of Mr Paul Linus Herrling be disallowed on this basis.

We note that Resolution 62.28 4(c) requires the DG “to establish a roster of experts comprising all the nominations submitted by the regional directors”. We argue that all of the names of the experts on this roster should be provided to the EB, not just the proposed members of the Group.

We note the lack of career detail provided regarding the proposed members. We believe that a brief CV should have been provided with each name so that the nature of the expertise that the proposed members bring to the Group might be clear to the EB.

We recommend that EB approval of this list be deferred pending the provision and consideration of these additional data.

4.4 Health-related Millennium Development Goals

Secretariat note: WHO’s role in the follow-up to the high-level plenary meeting of the sixty-fifth session of the United Nations General Assembly on the review of the Millennium Development Goals (September 2010)

The report includes information on the progress made in the implementation of resolutions WHA63.15 and WHA63.24, the latter of which expanded the coverage of the annual report on the monitoring of the achievement of the health-related Millennium Development Goals to include an account of progress towards achievement of
Millennium Development Goal 4 to reduce child mortality: prevention and treatment of pneumonia. At the request of a Member State, the report also presents an overview of WHO’s engagement in the high-level plenary meeting on the review of the Millennium Development Goals and the follow-up activities, describing the key health outcomes, implications for WHO and for countries, and required actions to achieve the Goals in the next five years.

PHM Comment

In Document EB128/7 the Secretariat reports on progress towards achievement of health related Millennium Development Goals and particularly Goal 4 (to reduce child mortality - through the prevention and treatment of pneumonia).

This report is focused largely on the technical interventions which will form part of any health development program but is very thin with respect to the political and economic context in which these interventions might be mounted. Despite the mention of the Commission on Social Determinants of Health there is little in this report which reflects the focus on equity and addressing upstream determinants which were elaborated by the CSDH. There is no reference to the constant pressure to liberalise trade which in many settings has exacerbated hunger and malnutrition.

The Secretariat is to be commended for its emphasis on the need for health system strengthening but we suggest that it could articulate more clearly the links between privatization policies forced on many L&MICs and the collapse of health systems;

These are issues which are not widely understood. The WHO’s leadership role demands that it takes the lead in researching, analyzing and developing appropriate policies to address these issues.

4.5 Health system strengthening

Secretariat note

The review will include a summary of current debate on national and global approaches to national health policies, strategies and plans, and the role of such dialogue in the achievement of better health outcomes and the mobilization and alignment of resources behind country priorities. The report will cover the building blocks for health systems including, at the request of a Member State, a review of early progress made in the implementation of the WHO Global Code of Practice on the International Recruitment of Health Personnel.

PHM Comment

A report (Document EB128/8) is provided by the Secretariat pointing towards strengthening the role of WHO in supporting national work towards health system strengthening.

This is an inadequate report.

Notwithstanding the promise of the annotation on the EB agenda, there is nothing in this report about the implementation of the WHO Global Code of Practice on the International Recruitment of Health Personnel. Indeed there is nothing about the workforce crisis, no reference to how brain drain in health is to be managed; no reference to the policy question of compensation of L&MICs whose exported professionals are staffing the hospitals and clinics of richer countries.

There is no mention in this report of the policies of the World Bank which since 1993 have promoted the horizontal stratification of health systems (private for the rich, social insurance for the middle and minimal safety net packages for the poor), nor is there any explicit analysis of the contribution of the disease specific funding bodies in promoting vertical fragmentation and internal
brain drain. There is no mention of IMF restrictions on ‘fiscal space’ in actually applying resources which may be available.

The report acknowledges that health care reform is fundamentally a political process but the focus on the rational logic of ‘best practice’ does not offer any guidance with respect to the politics of health care reform. In particular there is no mention of the advocacy, accountability and participatory role of civil society in driving health system reform.

4.6 Global immunization vision and strategy

Secretariat note

Resolution WHA61.15 requests the Director-General to report on progress made towards achievement of global immunization goals. The report describes the implementation of the Global Immunization Vision and Strategy 2006-2015 and gives an outline of efforts made by WHO, UNICEF, the Bill & Melinda Gates Foundation and other stakeholders to launch a 2011–2020 Decade of Vaccines and Immunization. The Board is invited to consider endorsement of the new initiative’s process and scope.

PHM Comment

A ‘one-size-fits-all’ approach in the introduction of new vaccines should be avoided. National priorities are not everywhere the same. The introduction of new vaccines should be subject to detailed needs assessment studies, cost-benefit analyses and public health impact assessments which recognize the specific circumstances of each member state. WHO should assist member states in undertaking such studies where appropriate. An urgent focus is required on adequately strengthening the vaccine delivery system without disrupting existing health services.

It is recognized that effective and efficient vaccine delivery requires and should be mediated through well functioning health systems. It is less widely recognized that a pre-occupation with immunisation delivery can disrupt health care delivery with serious negative consequences.

Sustainability is a key criterion in the financing of immunization programs. While Global Alliance on Vaccines and Immunizations (GAVI) may subsidize the cost of new vaccines for a few years, the capacity of member states to carry those costs in the longer term once the new vaccines have become part of their routine national health strategy needs to be considered. The projected costs of a full course of vaccination (para 25) underlines the importance of affordability.

Member states should be given technical assistance with respect to using the flexibilities provided under the *Trade Related aspects of Intellectual Property Rights (TRIPS) Agreement* to ensure affordability of vaccines.

The strategy should prioritise the provision of technical support and technology transfer to strengthen the capacity of member states to produce vaccines domestically. We recommend a focus on building research and manufacturing capacity in the public sector so governments are not over-reliant on the private vaccine industry and biotech industry.

The strategy mentions monitoring and surveillance of immunization but should also include reference to the monitoring of adverse events in the use of vaccines. Likewise the strategy should
include the promotion of safe injection, proper storage of vaccines and ensuring appropriate
compensation mechanisms for adverse events.


Secretariat note
Following the request to the Director-General in resolution WHA63.19 to submit a WHO HIV/AIDS strategy for
2011–2015, a broad consultation process has informed a draft global health sector strategy for HIV/AIDS structured
around four main goals: improving HIV outcomes; improving broader health outcomes; strengthening health
systems; and creating supportive environments. The Board is invited to consider the draft strategy.

PHM Comment

The progress report (EB128/10) does not discuss barriers to the implementation of the “Three
Ones” principle (one agreed HIV/AIDS action framework, one national AIDS coordinating authority, and
one agreed country-level monitoring and evaluation system) as provided for in WHA59.12 which urges
for the identification of barriers and strengthening of institutional capacity.

The Draft HIV/AIDS strategy should inform AIDS coordination and vice versa, with clear links
established between the two. The two items should not be discussed in isolation from one another.

Intellectual property rights, and the resulting unaffordability of diagnosis and treatment, should
be acknowledged as a barrier to reaching the ultimate objective of implementing the Three Ones
principles. The Draft HIV/AIDS Strategy mentions it, so it should be reflected here as well so that
coordination efforts could be directed its way (with the UNDP, for example).

According to WHA59.12, the DG is requested to prepare a plan of action for the implementation
of the recommendations of the Global Task Team, and to provide effective technical support at national
level. In the progress report (para. 92), there is mention of a UNAIDS technical support strategy to which
the WHO has contributed, and is “elaborating a plan to outline WHO’s role and contributions”. Member
States should ask for this plan of action (on WHO’s role and contributions) to be developed and set a
deadline for this.

Under the revised UNAIDS division of labour, according to the progress report (para 93), the WHO
continues to lead the health sector response to HIV. However, the report is not clear as to how the
contribution of the WHO in these areas will see improved coordination among multilateral and
international bodies, or, better, how such coordination of efforts could strengthen such an exercise.

With regard to monitoring and evaluation, it is not clear whether using the term “improving” the
performance of Joint UN Teams on AIDS (para. 94 of progress report), entails some monitoring and
evaluation mechanism in place (in line with the Task Team recommendations under Accountability and
Oversight). Developing the capacity of monitoring and evaluation at national level should also be
covered by technical support activities (covered under para. 92), because it is a crucial element for
sustainability of HIV response.

The close cooperation between WHO and the GF on technical support issues should not be
confined to countries who succeed in receiving GF. There are developing countries which are in need of
technical support, but which often fail the GF “application process”. They should not be deprived of such support.

It has been recognised that access to affordable HIV-related medicines is hampered by the failure of countries to use safeguards available in the TRIPS agreement (with reference to the Doha Declaration in a footnote). However, there is no reference to the failure of the para 6 system of the Doha Declaration in helping LDCs with no pharmaceutical manufacturing capacity access medicines (Canada-Rwanda case), and of its review process at the TRIPS council. The WHO, as the UN organisation mandated with health matters, should take the lead on this, rather than WTO on its own.

There is no mention of TRIPS-plus provisions in bilateral trade agreements through which developing countries give away their TRIPS safeguards.

There is a need for technical assistance on health-related IP matters, which should be specified under the implementation section (Table 6, p. 52), where the WHO collaborates with the UNDP. This is being called for at other UN organisations such as WTO and WIPO, and developing member states are also questioning the content of existing technical assistance programmes provided to developing countries. The WHO should take the lead on such health-related discussions, and there is also a need for more information about specific ways in which the WHO will contribute.

Under Health financing (p. 27) the draft strategy calls for the adoption of approaches to minimise out-of-pocket expenditure, but places mobilisation of donations for adequate funds as a first element, further reinforcing a vertical donor-centred approach. The immediate interpretation is that prices, hence big pharma commercial interests, are not to be negotiated.

The vertical approach, which is criticised for being unsustainable, should be addressed through strengthening national capacity, namely health regulatory and legislative capacities. Investing in local pharmaceutical manufacturing capacity also provides a sustainable solution away from the vertical approach.

4.8 Substandard/spurious/falsey-labelled/falsified/counterfeit medical products

Secretariat note
The Sixty-third World Health Assembly decided, inter alia, in WHA63(10) to establish a time-limited and results-oriented working group on substandard/spurious/falsey-labelled/falsified/counterfeit medical products. The outcome of the working group’s meeting held in December will be reported.

PHM Comment
There is an urgent need to ensure disengagement of WHO from the activities of IMPACT. Member state should ensure that WHO’s activities in the medicine areas should focus rational use of medicine and strengthening the regulatory capacity of member states to ensure quality, safety and efficacy of medicines instead of IP enforcement.

We urge member states to expedite the process of convening the working group prior to the upcoming WHA. We urge attention to ensure that the appointments process is transparent and free from conflicts of interest.
4.14 Prevention and control of non-communicable diseases

Secretariat note: WHO’s role in the preparation, implementation and follow-up to the high-level meeting of the United Nations General Assembly on the prevention and control of non-communicable diseases (September 2011)

The United Nations General Assembly decided, inter alia, in resolution A/RES/64/265 to convene a high-level meeting on non-communicable diseases in 2011. The resolution requires the Assembly to hold consultations on the scope, modalities, format and organization of the high-level meeting and requests the Secretary General to submit a report to the General Assembly at its Sixty-fifth session on the global status of non-communicable diseases. The report describes WHO’s plan for participation in and contribution to the preparations for the high level meeting, including the co-organization of an international ministerial conference on non-communicable diseases and healthy lifestyles in Moscow, as well as other implementation activities. Discussion of this topic by the Board also forms part of the consultative preparations.

PHM Comment

This report (EB128/17) describes WHO’s preparations for the High Level Meeting on NCDs in September 2011.

In the Annex summarizing previous events leading up to this meeting there is no reference to the work of the Commission on Social Determinants and Health. The CSDH emphasized the importance of looking at the equity dimensions as well as the disease process. Clearly there are important equity dimension to the incidence and prevalence of NCDs and these variations are closely linked to the social and environmental factors; not just individual behaviours.

Clause 9 of the report notes that WHO has organized informal consultations with representatives of nongovernmental and civil society organizations and the private sector. PHM is concerned that these discussions should not be restricted to those NGOs and CSOs which advocate for the prevention and treatment of particular disease groups. Having regard to the breadth of issues raised by the equity and the social determinants dimensions of NCDs it would be appropriate to consult with a broad range of NGOs and CSOs whose work is focused on various aspects of equity and social determinants also.

We urge that the materials produced for these consultation and the outcomes documents are posted on the WHO website. We urge that the regional consultation meetings should be open to a full range of NGOs and CSOs. We suggest the mounting of a web based consultation after the release of the foreshadowed WHO report.

4.15 Infant and young child nutrition: implementation plan

Secretariat note

The paper presents the outline of a comprehensive implementation plan on infant and young child nutrition and describes the process for developing the plan as a central component of a global, multisectoral nutrition framework, as requested in resolution WHA63.23.

PHM Comment

This is an important area and PHM will be following the development of the implementation plan closely. We suggest that EB members underline the importance of a transparent consultation process
including the publication on the web of all submissions to the consultation including particularly those coming from private sector.

4.16 Child injury prevention

Secretariat note
The Board discussed the item at its 127th session, including the text of a draft resolution, and agreed to defer further consideration to its 128th session. The report and the draft resolution are re-presented for consideration.

PHM Comment
There is no reference to the child injuries and death incurred during wars, military conflict, political instability and other forms of violence. WHO should recognize the contribution of these factors to child ill-health, injury and death.

4.17 United Nations Decade for Action for Road Safety: draft action plan

Secretariat note
In March 2010, in resolution A/64/255, the United Nations General Assembly proclaimed the period 2011–2020 as the Decade of Action for Road Safety, envisaging a significant role for WHO. The Secretariat report describes the main elements of a draft plan of action for the Decade. The Board is invited to consider the draft plan.

PHM Comment
It is not clear that the reference to a draft plan in the Secretariat note is correct. Document EB128/20 states (para 17) that the Plan has been finalized.

The ‘finalised’ plan does not give due weight to appropriate urban planning and the reduction in the number of automobiles on the roads. This is closely linked to the pressures and processes of urbanization which were fully explored in the Report of the Commission on Social Determinants of Health (to which reference is not made in this draft plan).

5. The future of financing for WHO

Secretariat note
The Director-General undertook to report to the Board the views of Member States on issues raised following the informal consultation on the Future of Financing for WHO in January 2010. The report will synthesize responses to the web consultation conducted between April and October as well as discussions held during the meetings of the Regional Committees in 2010. The January consultation acknowledged that the future of WHO’s financing has to be based on an understanding of WHO’s changing role and the nature of its core business. The report will therefore highlight areas of consensus and divergence in relation to priority setting, core business, and WHO’s governance role in global health.

PHM Comment
The WHO faces a financial crisis and its legitimacy is under attack. This paper (EB128/21) and the process it foreshadows are to be welcomed.

Funding
The proportion of voluntary (extra-budgetary) funds relative to assessed contributions (regular budget) from Member States continues to increase, raising the concern that priority setting by WHO
may be skewed by special interests and that WHO may be unable to fulfill its constitutional mandate and respond to the real health needs of populations.

An analysis of the 2012-2013 proposed budget (EB128/22)\(^1\) reveals low allocations to areas of work relating to root causes of avoidable disease and death\(^2\), and a strong focus on medicines, diagnostics and other health technologies.

In the area of communicable diseases, activities are almost exclusively focused on immunization/vaccination. This is despite the fact that the diseases of poverty - as the name suggest and public health history shows - require attention to the meeting of basic needs for health such as food, water, adequate sanitation and decent housing.

WHO’s work, as described in EB128/24\(^3\), focuses overwhelmingly on treatment to the detriment of health promotion, prevention and rehabilitation. Health promotion itself appears to be restricted to individual behavior change while structural causes receive inadequate attention.

We highlight the following statement by the DG in 128/21:

*For this reason, Member States are urged to give serious consideration to the issue of increasing assessed contributions and, where appropriate, revisiting national policies that restrict their growth.*

We suggest that the EB mandate the Secretariat to develop a sustainable financing plan for the WHO, to be placed at the next WHA. The plan should be premised on increased assessed contributions of member states, with a view to securing the independent role of the WHO, its continuing and expanded role in providing stewardship to global health issues and to reverse the present 20:80 division in WHO’s finances. Such a plan should also propose mechanisms that ensure that voluntary and donor contributions are not channeled for specified programmes, but are free to be used to promote the overall goals of the WHO that are collectively decided upon by member states. The plan should also propose a code of conduct on voluntary donations, so as to prevent conflict of interest between donor priorities and the member state driven agenda of the WHO.

*Core business*

The discussion of core functions represents a significant step back from the Core Functions outlined in the WHO Constitution, Article 2. The proposition that WHO should withdraw from its responsibilities regarding health in development should be opposed. This function is mandated in the Constitution and must be properly addressed.

PHM believes that the WHO Constitution mandates WHO to take the leadership role with respect to the coordination of international decision making on health matters. This should include holding the large donors to account with respect to the effectiveness and coordination of their technical and funding roles. It is not consistent with WHO’s mandate to withhold commentary on the large donors because they also provide tied funds to WHO.

---

\(^1\) *Medium Term Strategic Plan 2008-2013 and Proposed Programme Budget 2012-2013 (EB128/24).*

\(^2\) *Strategic Objectives 7, 8 and 9: social and economic determinants of health, healthier environment, and nutrition and food safety, respectively.*

\(^3\) *Programme Budget 2008-2009: performance assessment (EB128/22)*
By way of illustration we cite WHO’s work on the rational use of medicines which attracts virtually no funds. In contrast the huge expenditures on pharmaceutical marketing contribute in many ways to the over-use and inappropriate use of medicines. WHO priorities should not be shaped by the availability of funds.

PHM is concerned about the repeated statements that WHO is a technical body which we take as code for the withdrawal from a range of contested issues. Health is political as well as technical and WHO must accept the responsibility of engaging in the politics of health as well as advising on technical issues. (Virchow reminds us that ‘medicine is a social science, and politics is nothing else but medicine on a large scale’.)

**Mainstreaming cross cutting issues**

PHM is concerned that the ‘mainstreaming’ of ‘cross-cutting issues’ will lead to the neglect of such issues, partly because there will be no internal champions of such issues.

*The next step will be to implement a corporate approach to mainstreaming cross-cutting issues, such as health promotion, gender, human rights and social determinants. These activities are part of core business of WHO, but will be reflected in work across the Organization, rather than relying on separate departments to champion their cause.*

The neglect of the insights of the Commission on Social Determinants in many of the papers submitted to this EB meeting illustrates this. Likewise the paper on integrating gender analysis and actions into the work of WHO (resolution WHA60.25) focuses entirely on the corporate policies of WHO and does not consider the huge burden of disease globally which is rooted in gender inequality.

**Staffing**

The discussion of staffing policies in this report is superficial and does not appear to reflect a close analysis of the kind of workforce required to carry the functions of WHO. We are aware of widespread concerns about the prevailing human resource management practices in the secretariat and are concerned that full endorsement of the remarks on staffing contained in this report could further damage the capability of WHO. In particular, with the financial crisis facing WHO and the prospect of widespread retrenchments we are apprehensive that WHO will increasingly take its technical advice from the private sector or through in-kind ‘donations’ from high income countries.

**Geographical representation**

We note the geographical representation policy and the circulating concerns that even while achieving geographical representation there has been a practice of recruiting graduates of a small number of prestigious universities in a few high income countries. This ensures that the perspectives of those countries are fully represented even while appearing to meet the geographical representation policy. Further we are advised that the widespread use of short term casual staff is in some cases a device to avoid geographical representation.

**10.1. Control of Leishmaniasis**

**Secretariat note**

*Document number EB128/33 reports that the WHO Expert Committee on the Control of Leishmaniases has met and updated the two-decade old guidelines on the control of Leishmaniasis.*
The Report by the Secretariat to the 60th World Health Assembly (A60/10 dated 22 March 2007) makes three crucial points:

- ... the disease is not notifiable or is frequently undiagnosed, especially where there is no access to medication.
- ... for cultural reasons and lack of access to treatment, the case-fatality rate is three times higher in women than in men.
- The number of cases is increasing, mostly because of gradually more transmission in cities, displacement of populations, exposure of people who are not immune, deterioration of social and economic conditions in outlying urban areas, malnutrition (with consequent weakening of the immune system), and coinfection with HIV.

Leishmaniasis cannot be controlled without addressing these bottlenecks. We suggest that the Expert Committee review these issues and give specific recommendations to address the three key issues highlighted above. We note that the WHO’s Commission on Social Determinants of Health has given many wide ranging recommendations which could adapted for addressing these issues.

**We request that an updated report be submitted in the upcoming World Health Assembly.**

The Report of the WHO Expert Committee on the Control of Leishmaniases (WHO Technical Report Series, No 949) should be publicly and freely available for dissemination⁴.

### 10.2 Progress reports

#### 10.2 L. Progress in the rational use of medicines (resolution WHA60.16)

From 1986, there have been 14 resolutions related to rational use of medicines⁵. In spite of very clear policies being in place, majority of countries have yet to tackle rational use of medicines in their national plans and commit resources as recommended in the resolutions. The WHO database on use of medicines in primary care in developing countries and countries in transition for the period 2004–2009, reveals that only 50% of prescriptions issued in the public sector adhered to clinical guidelines, whereas in the private-for-profit sector during the same period prescription adherence was only 30%.

In Resolution WHA60.16 the Director General is urged to strengthen the leadership and evidence-based advocacy role of WHO in promoting rational use of medicines. WHO is also urged to strengthen WHO’s technical support to Member States in their efforts to establish or strengthen, where appropriate, multidisciplinary national bodies for monitoring medicine use, and implementing national programmes for the rational use of medicines. The resolution also recommends the strengthening of the coordination of international financial and technical support for rational use of medicines and to promote research for rational medicine use at all levels of the health sector, both public and private.

It is evident from the progress report that the WHO has not invested resources to follow through these recommendations. Neglecting the implementation of the resolution will have lasting negative impacts.

---

⁴ It is currently a paid publication. See WHO website at [http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=10&codcch=949](http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=10&codcch=949)

⁵ WHA39.27, WHA41.16, WHA41.17, WHA45.27, WHA45.30, WHA47.13, WHA47.16, WHA43.20, WHA47.12, WHA49.14, WHA52.19, WHA51.9, WHA54.11 and WHA60.16
repercussions on public health. For instance- the rational use of antibiotics forms a significant part of the effort to manage antimicrobial resistance.

It is not possible to address the rational use of medicines without addressing the pressures for irrational and over use of medicines through pharmaceutical marketing. WHO’s inaction suggests that dependence on assistance from the pharmaceutical industry in certain other areas may have discouraged proper attention to this field.

Likewise we note the continuing pressures from the international financial institutions for the privatization of health care and note the incentives in privatized health care for over prescribing and over servicing and the greater difficulty in regulating these distortions.

It is apparent that this field has been grossly neglected in terms of both financing and staffing for at least a decade. We suggest that the EB might ask the DG to prepare report on the implementation of WHA60.16 including separately for each item the expenditures, the number of staff are working on the item; and what has been achieved.

In closing I reiterate our warm anticipation of perhaps chatting with you during the course of the EB meeting. A number of our members will be attending the EB meeting and would be honoured to chat through some of the above issues with you.

Yours sincerely

Hani Serag
Associate Global Coordinator, People’s Health Movement
globalsecretariat@phmovement.org